Nixodine vapes, offered in sweet flavors, are widely available online, raising concerns because they are marketed as “nicotine‑free” while still promising a strong, satisfying hit, features that may appeal to youth. These products contain a substance called nixodine rather than nicotine.
While nicotine is an alkaloid derived from tobacco leaves, nixodine is created in labs (6-Methylnicotine). Some manufacturers claim it’s derived from a vitamin B blend.
Nixodine won’t metabolize into cotinine, so it often doesn’t show on urine, blood, saliva or other tests.
Manufacturers claim that, since nixodine isn’t derived from tobacco, it also avoids the nitrosamines associated with those products. However, the federal government has not tested this claim.
The FDA does not currently regulate nixodine products, though officials have stated that it may regulate nicotine alternatives if they become a problem.
Yet the FDA has not authorized the products for sale.
“Products like nixodine are designed to mimic nicotine’s effects while avoiding its legal definition, and that creates real concerns about products slipping through regulatory gaps,” UW‑CTRI Director Dr. Hasmeena Kathuria said. “As a pulmonologist and critical care physician, I worry about young people being drawn to these products under the impression that they’re safer or risk‑free.”
Many nixodine vapes come in youth‑appealing flavors such as “Baja Mango,” “Vanilla Custard,” and “Cinnamon Blend,” and some devices advertise up to 20,000 puffs, features that raise additional concerns about addiction and youth uptake.